Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.
about
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications.Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions.Incidence and Characteristics of Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion in a Representative Canadian Cohort.Artifacts in optical coherence tomography.
P2860
Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Retinal vein occlusion and mac ...... clinical value of ranibizumab.
@ast
Retinal vein occlusion and mac ...... clinical value of ranibizumab.
@en
type
label
Retinal vein occlusion and mac ...... clinical value of ranibizumab.
@ast
Retinal vein occlusion and mac ...... clinical value of ranibizumab.
@en
prefLabel
Retinal vein occlusion and mac ...... clinical value of ranibizumab.
@ast
Retinal vein occlusion and mac ...... clinical value of ranibizumab.
@en
P2860
P356
P1476
Retinal vein occlusion and mac ...... clinical value of ranibizumab.
@en
P2093
Pearse A Keane
Srinivas R Sadda
P2860
P304
P356
10.2147/OPTH.S13774
P407
P577
2011-06-09T00:00:00Z